作者
Erin K McCreary, Ravina Kullar, Matthew Geriak, Evan J Zasowski, Khulood Rizvi, Lucas T Schulz, Krista Ouellette, Logan Vasina, Fadi Haddad, Michael J Rybak, Marcus J Zervos, George Sakoulas, Warren E Rose
发表日期
2020/1
期刊
Open Forum Infectious Diseases
卷号
7
期号
1
页码范围
ofz538
出版商
Oxford University Press
简介
Background
Daptomycin and ceftaroline (DAP-CPT) have been used for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been compared with other therapies. This study provides an exploratory analysis of patients placed on DAP-CPT vs standard of care (SOC) for MRSAB.
Methods
This is a retrospective, matched cohort study MRSAB patients at 4 hospitals in the United States. Patients receiving DAP-CPT for ≥72 hours at any point in therapy were matched 2:1 when possible, 1:1 otherwise, to SOC, first by infection source, then age and renal function. SOC was empiric treatment with vancomycin or daptomycin and any subsequent combination antibiotic(s), except for DAP-CPT.
Results
Fifty-eight patients received DAP-CPT with 113 matched SOC. Ninety-six percent of SOC received vancomycin, and 56% (63 …
引用总数
20192020202120222023202411416131717